Ninth International Congress on Targeted Therapies in Cancer

Venue: L’Enfant Plaza Hotel

Location: Washington, Washington DC, United States

Event Date/Time: Aug 20, 2010 End Date/Time: Aug 21, 2010
Report as Spam


The Ninth International Congress on Targeted Therapies in Cancer is designed to provide participants with cutting-edge information on novel targeted anticancer therapies now in development, including the most current clinical data on those agents as well as information on their mechanisms of action. The congress will provide a unique opportunity for medical oncologists, translational researchers, and drug developers from academia and industry to learn from and interact with international leaders in novel therapeutic and drug discovery platforms and to obtain a preview of agents in development for the next generation of cancer therapy. Topics to be discussed include DNA repair and PARP inhibition, the tumor microenvironment, cell surface receptors, mediators of intracellular signaling, regulators of cellular processes such as protein homeostasis and apoptosis, and novel immunotherapeutic agents being developed in multiple tumor types.

Target Audience

This educational program is directed toward medical oncologists, translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. Other health care professionals interested in the treatment of cancer are also invited to attend.


480 L’Enfant Plaza, S.W.
Washington DC
United States

Additional Information

Learning Objectives At the conclusion of this congress, you should be able to: Discuss approaches to target the tumor microenvironment for cancer therapy Describe approaches to inhibit DNA repair and disrupt the cell cycle in cancer cells Evaluate data on inhibitors of novel signaling pathways in cancer therapy Assess the role of new imaging techniques in drug delivery and monitoring response Evaluate strategies to induce apoptotic signaling in tumor cells Appraise new approaches to develop immunotherapeutic agents in cancer therapy Discuss approaches to target protein homeostasis for cancer therapy Identify appropriate clinical trials of novel targeted agents that benefit specific groups of patients with cancer Continuing Education Information Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physicians’ Education Resource designates this educational activity for a maximum of 18.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.